Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Tiziana Life Sciences Ltd (TLSA)
Tiziana Life Sciences Ltd (TLSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,067
  • Shares Outstanding, K 102,270
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,400 K
  • 60-Month Beta 0.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.70
Trade TLSA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 04/24/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -327.19%)
  • Historical Volatility 26.06%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,484.47% on 03/22/23
  • IV Low 0.00% on 03/01/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 57
  • Volume Avg (30-Day) 10
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 591
  • Open Int (30-Day) 616

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4500 +4.42%
on 03/04/24
0.5400 -12.98%
on 02/14/24
-0.0578 (-10.95%)
since 02/02/24
3-Month
0.4500 +4.42%
on 03/04/24
0.6508 -27.80%
on 12/22/23
-0.1502 (-24.22%)
since 12/04/23
52-Week
0.4500 +4.42%
on 03/04/24
1.3928 -66.26%
on 04/19/23
-0.0777 (-14.19%)
since 03/03/23

Most Recent Stories

More News
Gevo's Cash Flow, Small Cap Buying Back Shares

GEVO shareholders may have been sold an empty promise of a sizable share buyback program, or so would bears say. Revenue breakthroughs may deliver the promise

TLSA : 0.4699 (-0.02%)
GEVO : 0.8573 (-5.93%)
TSLA : 188.14 (-7.16%)
NIO Could Bring A Pleasant Beat This Coming Quarter

Tesla's price cuts have initiated a full on war across the EV industry, however NIO has refused to follow along. This may present even more upside for the stock

TLSA : 0.4699 (-0.02%)
NIO : 5.33 (-7.79%)
TSLA : 188.14 (-7.16%)
LCID : 3.21 (-3.60%)
RIVN : 10.91 (-3.88%)
TCEHY : 34.7300 (-1.53%)
BYDDF : 24.1200 (-3.83%)
Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer

NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.4699 (-0.02%)
Tiziana Life Sciences Announces Resignation of CEO

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.4699 (-0.02%)
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice

NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling...

TLSA : 0.4699 (-0.02%)
TILS.LN : 58.500 (+8.33%)
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.4699 (-0.02%)
Tiziana Life Sciences PLC (TLSA: NASDAQ) Releases Research Report: Clinical Improvements for 2nd SPMS Patient

Zacks Small-Cap Research Note By John D. Vandermosten, CFA NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA)...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.4699 (-0.02%)
Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.4699 (-0.02%)
Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient

Research Note Clinical Results for Second SPMS Patient NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA)...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.4699 (-0.02%)
Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.4699 (-0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 0.5213
2nd Resistance Point 0.5030
1st Resistance Point 0.4865
Last Price 0.4699
1st Support Level 0.4517
2nd Support Level 0.4334
3rd Support Level 0.4169

See More

52-Week High 1.3928
Fibonacci 61.8% 1.0327
Fibonacci 50% 0.9214
Fibonacci 38.2% 0.8101
Last Price 0.4699
52-Week Low 0.4500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar